PTCHD3

Across TCGA pan-cancer cohorts, PTCHD3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTCHD3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PTCHD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTCHD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

BRCA, KIRC, and SKCM are the cancer types where PTCHD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.776	0.963	<.001	40	view →
KIRC	OS	Median	All	0.172	0.811	.002	12	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
UCEC	DFS	Median	All	0.898	0.614	.031	2	view →
LUSC	DFS	Median	All	0.710	0.384	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTCHD3–BRCA (OS)

Open the BRCA breakdown →